IV KENGREAL® (cangrelor). For Confidence During High-risk PCI Cases.*

KENGREAL is the only parenteral P2Y12 inhibitor for rapid platelet inhibition with quick offset.1

Patients at higher risk for periprocedural thrombotic events benefited from KENGREAL2

≥3 angiographichigh-risk lesion features~25% of patients had
See how KENGREAL performs in high-risk patients

*In a post hoc analysis of CHAMPION PHOENIX, the absolute benefit of KENGREAL increased progressively with the number of high-risk lesion features treated and was greatest for patients with ≥3.2

Platelet inhibition when you need it most

Learn about clinical cases where KENGREAL may be appropriate.

Emergent case–absorption issues

Emergent case–absorption issues
STEMI–morphine or fentanyl coadministration

STEMI
NSTEMI–high-risk anatomy

NSTEMI–high-risk anatomy
See the cases

Not actual patients. Patient symptoms will vary; individual clinical evaluation should be done to determine the best course of therapy.

>98% inhibition of platelet aggregation – Rapid onset within 2 minutes – Quick offset within 1 hour after discontinuation – Average elimination half-life of 3–6 minutes

Rapid onset, quick offset1

>98% inhibition of platelet aggregation in whole blood impedance aggregometry.3

Learn more about the pharmacology of KENGREAL

KENGREAL inhibition of thrombus formation
in vivo

In this 30-second video, see the effect of KENGREAL on the thrombotic response to laser-induced injury in the mouse cremaster muscle arteriole.3,4

Watch a video about KENGREAL clot inhibition in vivo

KENGREAL inhibition of thrombus formation in vivo

In this 30-second video, see the effect of KENGREAL on the thrombotic response to laser-induced injury in the mouse cremaster muscle arteriole.3,4

Information featured here includes in vivo data, the clinical significance of which has not been established.

Want more information on what you’ve seen here? Contact Us
22% relative risk reduction in MACE38% relative risk reduction in stent thrombosis

Relative risk reduction in periprocedural thrombotic events and proven safety

In CHAMPION PHOENIX, KENGREAL provided significant risk reduction vs clopidogrel in the composite outcome of MACE (death, MI, IDR, and ST) at 48 hours, and the individual outcome of ST.1,5 Patients receiving KENGREAL had no statistically significant increase in GUSTO-defined severe bleeding or need for transfusion.5 Bleeding events of all severities were more common with KENGREAL than with clopidogrel.1

See efficacy & safety

Dosing and administration

KENGREAL is administered as a bolus and infusion after reconstitution and dilution.1

Dosing and administration

KENGREAL is administered as a bolus and infusion after reconstitution and dilution.1

Watch the video
Kengreal Dosing and Administration video
info icon

Reach out to us for more information and updates, or to be contacted by a rep.

Contact us
Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Indication

KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Please see Full Prescribing Information.

References: 1. KENGREAL® (cangrelor) Prescribing Information. 2020. 2. Stone GW, Généreux P, Harrington RA, et al. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018;39(46):4112-4121. 3. Data on file. Chiesi USA, Inc. 4. Stalker TJ, Traxler EA, Wu J, et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013;121:1875-1885. 5. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-1313.